Switch theme
Sign up to access all valuation multiples
Azenta Inc is a provider of life sciences solutions, enabling impactful breakthroughs and therapies to market faster. It provides a full suite of reliable cold-chain sample management solutions and genomic services across areas such as drug development, clinical research and cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. The company has three reportable segments that are Sample Management Solutions, Multiomics, and B Medical Systems. It generates a substantial part of its revenue from its Sample Management Solutions segment.
1978
3.3K+
LTM Revenue $616M
LTM EBITDA $59.1M
$949M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Azenta has a last 12-month revenue (LTM) of $616M and a last 12-month EBITDA of $59.1M.
In the most recent fiscal year, Azenta achieved revenue of $656M and an EBITDA of $17.8M.
Azenta expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Azenta valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $616M | XXX | $656M | XXX | XXX | XXX |
| Gross Profit | $278M | XXX | $263M | XXX | XXX | XXX |
| Gross Margin | 45% | XXX | 40% | XXX | XXX | XXX |
| EBITDA | $59.1M | XXX | $17.8M | XXX | XXX | XXX |
| EBITDA Margin | 10% | XXX | 3% | XXX | XXX | XXX |
| EBIT | $5.2M | XXX | -$72.9M | XXX | XXX | XXX |
| EBIT Margin | 1% | XXX | -11% | XXX | XXX | XXX |
| Net Profit | $20.6M | XXX | -$164M | XXX | XXX | XXX |
| Net Margin | 3% | XXX | -25% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Azenta's stock price is $27.
Azenta has current market cap of $1.2B, and EV of $949M.
See Azenta trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $949M | $1.2B | XXX | XXX | XXX | XXX | $0.42 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Azenta has market cap of $1.2B and EV of $949M.
Azenta's trades at 1.5x EV/Revenue multiple, and 32.3x EV/EBITDA.
Equity research analysts estimate Azenta's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Azenta has a P/E ratio of 59.4x.
See valuation multiples for Azenta and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.2B | XXX | $1.2B | XXX | XXX | XXX |
| EV (current) | $949M | XXX | $949M | XXX | XXX | XXX |
| EV/Revenue | 1.5x | XXX | 1.5x | XXX | XXX | XXX |
| EV/EBITDA | 16.1x | XXX | 32.3x | XXX | XXX | XXX |
| EV/EBIT | 182.5x | XXX | -18.1x | XXX | XXX | XXX |
| EV/Gross Profit | 3.4x | XXX | n/a | XXX | XXX | XXX |
| P/E | 59.4x | XXX | -10.4x | XXX | XXX | XXX |
| EV/FCF | -8.8x | XXX | -71.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAzenta's last 12 month revenue growth is 0%
Azenta's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Azenta's rule of 40 is 7% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Azenta's rule of X is 9% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Azenta and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 0% | XXX | -1% | XXX | XXX | XXX |
| EBITDA Margin | 10% | XXX | 5% | XXX | XXX | XXX |
| EBITDA Growth | 37% | XXX | 24% | XXX | XXX | XXX |
| Rule of 40 | 7% | XXX | 4% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 9% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 5% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 51% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Australian Clinical Labs | XXX | XXX | XXX | XXX | XXX | XXX |
| Healius | XXX | XXX | XXX | XXX | XXX | XXX |
| Integral Diagnostics | XXX | XXX | XXX | XXX | XXX | XXX |
| Sonic Healthcare | XXX | XXX | XXX | XXX | XXX | XXX |
| Bangkok Dusit Medical Services | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Azenta acquired XXX companies to date.
Last acquisition by Azenta was XXXXXXXX, XXXXX XXXXX XXXXXX . Azenta acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Azenta founded? | Azenta was founded in 1978. |
| Where is Azenta headquartered? | Azenta is headquartered in United States of America. |
| How many employees does Azenta have? | As of today, Azenta has 3.3K+ employees. |
| Who is the CEO of Azenta? | Azenta's CEO is Mr. John P. Marotta. |
| Is Azenta publicy listed? | Yes, Azenta is a public company listed on NAS. |
| What is the stock symbol of Azenta? | Azenta trades under AZTA ticker. |
| When did Azenta go public? | Azenta went public in 1995. |
| Who are competitors of Azenta? | Similar companies to Azenta include e.g. Australian Clinical Labs, Healius, Integral Diagnostics, Sonic Healthcare. |
| What is the current market cap of Azenta? | Azenta's current market cap is $1.2B |
| What is the current revenue of Azenta? | Azenta's last 12 months revenue is $616M. |
| What is the current revenue growth of Azenta? | Azenta revenue growth (NTM/LTM) is 0%. |
| What is the current EV/Revenue multiple of Azenta? | Current revenue multiple of Azenta is 1.5x. |
| Is Azenta profitable? | Yes, Azenta is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Azenta? | Azenta's last 12 months EBITDA is $59.1M. |
| What is Azenta's EBITDA margin? | Azenta's last 12 months EBITDA margin is 10%. |
| What is the current EV/EBITDA multiple of Azenta? | Current EBITDA multiple of Azenta is 16.1x. |
| What is the current FCF of Azenta? | Azenta's last 12 months FCF is -$108M. |
| What is Azenta's FCF margin? | Azenta's last 12 months FCF margin is -18%. |
| What is the current EV/FCF multiple of Azenta? | Current FCF multiple of Azenta is -8.8x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
